2. Academic Validation
  3. Synthesis and biological evaluation of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110alpha inhibitors

Synthesis and biological evaluation of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110alpha inhibitors

  • Bioorg Med Chem Lett. 2007 May 1;17(9):2438-42. doi: 10.1016/j.bmcl.2007.02.032.
Masahiko Hayakawa 1,  Hiroyuki Kaizawa,  Hiroyuki Moritomo,  Tomonobu Koizumi,  Takahide Ohishi,  Mayumi Yamano,  Minoru Okada,  Mitsuaki Ohta,  Shin-ichi Tsukamoto,  Florence I Raynaud,  Paul Workman,  Michael D Waterfield,  Peter Parker
Affiliations

Affiliation

  • 1 Drug Discovery Research, Astellas Pharma Inc., 5-2-3 Tokodai, Tsukuba, Ibaraki 300-2698, Japan. [email protected]
PMID: 17339109 DOI: 10.1016/j.bmcl.2007.02.032
Abstract

4-Morpholin-4-ylpyrido[3',2':4,5]thieno[3,2-d]pyrimidine 2a was discovered in our chemical library as a novel p110alpha inhibitor with an IC(50) of 1.4 microM. By structural modification of 2a, the 2-aryl-4-morpholinopyrido[3',2':4,5]furo[3,2-d]pyrimidine derivative 10e was discovered as a p110alpha inhibitor with approximately 400-fold greater potency than 2a. Evaluation of isoform selectivity showed that 10e is a potent inhibitor of p110beta. Furthermore, 10e showed anti-proliferative activity in various cell lines, including multi-drug resistant MCF7/ADR-res cells, and was effective against HeLa human cervical tumor xenografts in nude mice.

Figures